Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,893 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Patients Clear all

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: adaptive stereotactic body radiation therapy (SBRT) with a SIB; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions: YM598; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions: Relugolix Pill, Ritonavir, Itraconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Prostate SBRT with concurrent boost to intraprostatic lesion(s); Radiation
Lead sponsor: Rocky Mountain Cancer Centers; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Littleton, Colorado

Conditions: Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions: (R)-9bMS; Drug
Lead sponsor: TechnoGenesys, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Genistein Combined Polysaccharide (GCP); Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostatic Neoplasms
Interventions: Exisulind; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Thalidomide, leuprolide acetate, goserelin, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 9
States / cities: Fort Lauderdale, Florida • New Orleans, Louisiana • Bethesda, Maryland + 6 more

Conditions: Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Interventions: Evofosfamide, Zalifrelimab, Balstilimab; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Liposome Entrapped Docetaxel (LE-DT); Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Portland, Oregon

Conditions: Cancer
Interventions: management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Prostate Cancer
Interventions: Provider-level and patient education at end of study, Provider-level and patient-level; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Vitamin E; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions: pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: NanoKnife Procedure; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, Minnesota

Conditions: Prostate Cancer, PI-RADS 3 Prostate Lesion
Interventions: PET Imaging with Flotufolastat F 18; Diagnostic Test
Lead sponsor: SimonMed Imaging; Other
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 3 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 40
States / cities: Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more

Conditions: Prostate Cancer
Interventions: walking exercise, weight training, Usual Care; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 40
States / cities: Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more

Conditions: Prostate Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,051 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 3
States / cities: Voorhees Township, New Jersey • Albuquerque, New Mexico • Houston, Texas

Search by objective public record fields.

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Effects of GCP on Prostate Cancer.

Exisulind Versus Placebo After Surgical Removal of the Prostate

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Physician- and Patient-based Barriers to NGS Testing

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Quality of Life Study for Prostate Cancer Patients